1795 Mei-Shih: Alvogen Korea Subsidiary Secures Korean Approval for Anti-PD-1 Antibody SERPLUMAR

Release Date: July 7, 2026 Statement Date: July 6, 2026 Statement Time: 11:34 Company Code: 1795 Company Name: Mei-Shih Subject: Clarification of Media Report Applicable Clause: Clause 51 Event Date: July 6, 2026

1. Event Date: July 6, 2026 2. Company Name: Alvogen Korea Co., Ltd. 3. Relationship to Company: Subsidiary 4. Cross-shareholding Ratio: Not applicable 5. Media Outlet: China Times Business 6. Report Content: Mei-Shih (1795) has achieved another milestone in its oncology portfolio. Its wholly-owned subsidiary, Alvogen Korea, has announced with Shanghai Fosun Honglin that SERPLUMAR (serplulimab), an independently developed anti-PD-1 monoclonal antibody, has been approved by South Korea's Ministry of Food and Drug Safety (MFDS) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This approval provides a new immunotherapy option for South Korean patients and further strengthens Mei-Shih's strategic positioning in the Asian oncology market. 7. Reason for Occurrence: Media report 8. Response Measures: SERPLUMAR (serplulimab) is a humanized anti-PD-1 monoclonal antibody independently developed by Fosun Honglin. As stated in the press release issued by Mei-Shih on July 2, 2026: "Mei-Shih Pharmaceutical (hereinafter 'Mei-Shih', Taiwan Stock Exchange code: 1795), through its wholly-owned subsidiary Alvogen Korea, and Shanghai Fosun Honglin Biotechnology Co., Ltd. (2696.HK, hereinafter 'Fosun Honglin'), today announced that SERPLUMAR (serplulimab) has been approved by South Korea's Ministry of Food and Drug Safety (MFDS) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). SERPLUMAR is a humanized anti-PD-1 monoclonal antibody independently developed by Fosun Honglin, offering a new immuno-oncology treatment option for ES-SCLC patients in South Korea." 9. Other Matters to be Disclosed: None